Kyowa Kirin Co.
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Kyowa Kirin Co. sits in the top decile of US sponsors by registered trial count (#626 of 15,742 sponsors by registered trial count).
Kyowa Kirin Co.: 25 sponsored US clinical trials, 3 recruiting.
Kyowa Kirin Co. sponsors 25 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 15 completed. 4 of these trials are in Phase 3-4 (later-stage) and 21 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is X-linked Hypophosphatemia, with 2 trials.
Top-decile sponsor footprint
Kyowa Kirin Co. ranks in the top decile of sponsors by registered trial count (#626 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
15 of 20 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (75.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
25 total, page 1 of 1
A Phase 1/2 Study of KK2430 in Participants With Hematologic Neoplasms
NCT07629726
A First-in-human Study of KK8123 in Adults With X-linked Hypophosphatemia
NCT06525636
A Study of KK2269 in Adult Participants With Solid Tumors
NCT06266299
Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration
NCT06116890
Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema
NCT06116916
A Study to Evaluate Abuse Potential of Istradefylline
NCT02609477
Long Term Study of Istradefylline in Subjects With Moderate to Severe Parkinson's Disease
NCT02610231
Effect of Mild Hepatic Impairment on the Pharmacokinetics of Istradefylline
NCT02256033
The Effect of Rifampin on the Metabolism of Istradefylline in Healthy Volunteers.
NCT02174250
A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease
NCT01968031
An Extension Study of KRN23 in Adults With X-Linked Hypophosphatemia
NCT01571596
A Repeated Study of KRN23 in Adults With X-Linked Hypophosphatemia
NCT01340482
Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer
NCT01279291
Safety, Tolerability, and Efficacy Study in Subjects With Advanced or Metastatic Breast Cancer
NCT01199367
Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001
NCT01226472
A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
NCT01063907
Safety Study to Evaluate KW-2450 in Subjects With Advanced Solid Tumor
NCT00921336
Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell Lymphoma
NCT00888927
Safety Study of Electrocardiogram (ECG) Effects of Sancuso® (Granisetron TDS)
NCT00890565
Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer
NCT00838578
Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Study of KW-2449 in Acute Myelogenous Leukemia (AML) (Protocol Number: 2449-US-002)
NCT00779480
A Study of KRN23 in X-linked Hypophosphatemia
NCT00830674
Phase 1/2 Study of Anti GM-2 Monoclonal Antibody To Treat Multiple Myeloma
NCT00775502
Efficacy and Safety of Sublingual Fentanyl Tablets in Treatment of Breakthrough Pain in Cancer Patients.
NCT00262678
Long-term Safety Study of Sublingual Fentanyl Tablets in Cancer Patients
NCT00263575
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 18 |
| Phase 2 | 3 |
| Phase 3 | 4 |
Therapeutic Areas
What is open in the Kyowa Kirin Co. pipeline
3 recruiting of 25 indexed (12% open); 15 completed (60%).
Phase mix: 4 late (III/IV) vs 21 early (I/II) (early-phase heavy).
Top condition: X-linked Hypophosphatemia (2 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Kyowa Kirin Co.: open-pipeline peers nationwide
Peers matched on 25 registered trials and 12% open enrollment, not the therapeutic-area sidebar.
Kyowa Kirin Co. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 25 trials (± recruiting share)
- Arcus Biosciences · 25 trials · 12% recruiting
- Arcutis Biotherapeutics · 25 trials · 8% recruiting
- Ardelyx · 25 trials · 12% recruiting
- Drexel University College of Medicine · 25 trials · 0% recruiting
Sponsors near 12% open enrollment (± trial volume)
- Takeda · 12% recruiting · 408 trials
- East Carolina University · 12% recruiting · 58 trials
- National Institute of Dental and Craniofacial Research (NIDCR) · 12% recruiting · 91 trials
- Antonios Likourezos · 12% recruiting · 33 trials
Related
What to do with this Kyowa Kirin Co. page
25 registered trials is a research-attention snapshot, not an endorsement of Kyowa Kirin Co. or any single study.
- 3 of Kyowa Kirin Co.'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- X-linked Hypophosphatemia is the condition Kyowa Kirin Co. studies most, compare against other sponsors active in the same condition before evaluating a specific study. See X-linked Hypophosphatemia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Kyowa Kirin Co. pipeline card: 25 registered trials from official public datasets.Report a data error.